Kocaman Gökhan, Kahya Yusuf, Konuk Balcı Buse Mine, Yenigün Bülent Mustafa, Özkan Murat, Özakıncı Hilal, Karasoy Duru, Yüksel Cabir, Enön Serkan, Kayı Cangır Ayten
Department of Thoracic Surgery, Medicine Faculty of Ankara University, Ankara, Türkiye.
Department of Pathology, Moffit Cancer Center, Florida, USA.
Turk Gogus Kalp Damar Cerrahisi Derg. 2024 Jan 29;32(1):55-61. doi: 10.5606/tgkdc.dergisi.2024.25393. eCollection 2024 Jan.
This study aims to evaluate the oncological results of primary and secondary chest wall tumors treated with curative resections and to investigate possible prognostic factors.
Between January 2010 and December 2021, a total of 77 patients (53 males, 24 females; median age: 59 years; range, 3 to 87 years) who underwent curative resection for malignant chest wall tumors were retrospectively analyzed. Each tumor was staged according to its histological type. Age, sex, tumor diameter, tumor type (primary/secondary), histological tumor type, grade, stage, complete resection, rib resection, reconstruction, neoadjuvant and adjuvant therapy, recurrence, and survival data were recorded.
Of the chest wall tumors, 33 (42.9%) were primary and 44 (57.1%) were secondary (local invasion, metastasis). Nine (11.7%) patients had positive surgical margins. Chest wall resection was most commonly performed due to lung cancer invasion (46.8%), followed by Ewing sarcoma (13%). Recurrence was observed in 34 (44.2%) patients. The five-year recurrence-free survival rate was 42.7% and the five-year overall survival rate was 58.6%. There was no significant difference between the primary and secondary tumors in terms of recurrence-free and overall survival (p=0.663 and p=0.313, respectively). In the multivariate analysis, tumor grade and rib resection were found to be independent prognostic factors for both recurrence-free survival (p=0.005 and p<0.001, respectively) and overall survival (p=0.048 and p=0.007, respectively).
Successful oncological results can be achieved in wellselected patients with primary and secondary chest wall tumors. The grade of the tumor should be taken into account while determining the neoadjuvant or adjuvant treatment approach and surgical margin width. Rib resection should not be avoided when necessary.
本研究旨在评估采用根治性切除术治疗原发性和继发性胸壁肿瘤的肿瘤学结果,并调查可能的预后因素。
回顾性分析2010年1月至2021年12月期间77例行恶性胸壁肿瘤根治性切除术的患者(53例男性,24例女性;中位年龄:59岁;范围3至87岁)。根据组织学类型对每个肿瘤进行分期。记录年龄、性别、肿瘤直径、肿瘤类型(原发性/继发性)、组织学肿瘤类型、分级、分期、完整切除、肋骨切除、重建、新辅助和辅助治疗、复发及生存数据。
胸壁肿瘤中,33例(42.9%)为原发性,44例(57.1%)为继发性(局部侵犯、转移)。9例(11.7%)患者手术切缘阳性。胸壁切除最常见的原因是肺癌侵犯(46.8%),其次是尤因肉瘤(13%)。34例(44.2%)患者出现复发。五年无复发生存率为42.7%,五年总生存率为58.6%。原发性和继发性肿瘤在无复发生存率和总生存率方面无显著差异(分别为p = 0.663和p = 0.313)。多因素分析显示,肿瘤分级和肋骨切除是无复发生存率(分别为p = 0.005和p < 0.001)和总生存率(分别为p = 0.048和p = 0.007)的独立预后因素。
精心挑选的原发性和继发性胸壁肿瘤患者可取得成功的肿瘤学结果。在确定新辅助或辅助治疗方法及手术切缘宽度时应考虑肿瘤分级。必要时不应避免肋骨切除。